Mouse complement receptor related gene y/p65-neutralized tumor vaccine induces anti-tumor activity in vivo

Journal of Immunology

Volumn 173, Issue 1, 2004, Pages 205-213

  Ohta, Rieko ^a,b   Kondor, Natalie ^a   Dohi, Natsuki ^a   Tomlinson, Stephen ^b   Imai, Masaki ^b   Holers, V Michael ^c   Okada, Hidechika ^a   Okada, Noriko ^a  

^a NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C3; COMPLEMENT RECEPTOR; IMMUNOGLOBULIN M; MEMBRANE PROTEIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 5D5; NEUTRALIZING ANTIBODY; REGULATOR PROTEIN; TUMOR VACCINE; UNCLASSIFIED DRUG;

ADOLESCENT; ANIMAL CELL; ANTIBODY TITER; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST TUMOR; CANCER CELL CULTURE; CELL STRAIN METH A; CELL STRAIN MM46; COMPLEMENT ACTIVATION; COMPLEMENT DEPOSITION; COMPLEMENT RECEPTOR RELATED GENE Y; CONTROLLED STUDY; CRRY GENE; CYTOTOXIC T LYMPHOCYTE; FEMALE; FIBROSARCOMA; GENE; GENE EXPRESSION; IMMUNE RESPONSE; IMMUNOGENICITY; IN VIVO STUDY; IRRADIATION; MOUSE; MOUSE STRAIN; NONHUMAN; P65 GENE; PRIORITY JOURNAL; SURVIVAL; TUMOR GROWTH; TUMOR IMMUNITY; VACCINATION;

EID: 2942731633     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.173.1.205     Document Type: Article

References (48)

1. Okada, H., H. Tanaka, and N. Okada. 1983. Prevention of complement activation on the homologous cell membrane of nucleated cells as well as erythrocytes. Eur. J. Immunol. 13:340.
2. Okada, N., T. Yasuda, and H. Okada. 1982. Restriction of alternative complement pathway activation by sialosylglycolipids. Nature 299:261.
3. Ahearn, J. M., and D. T. Fearon. 1989. Structure and function of the complement receptors, CR1 (CD35) and CR2 (CD21). Adv. Immunol. 46:183.
4. Lublin, D. M., and J. P. Atkinson. 1989. Decay-accelerating factor: biochemistry, molecular biology, and function. Annu. Rev. Immunol. 7:35.
5. Nicholson-Weller, A. 1992. Decay accelerating factor (CD55). Curr. Top. Microbiol. Immunol. 178:7.
6. Ballard, L., T. Seya, J. Teckman, D. M. Lublin, and J. P. Atkinson. 1987. A polymorphism of the complement regulatory protein MCP (membrane cofactor protein or gp45-70). J. Immunol. 138:3850.
7. Okada, N., R. Harada, T. Fujita, and H. Okada. 1989. A novel membrane glycoprotein capable of inhibiting membrane attack by homologous complement. Int. Immunol. 1:205.
8. Okada, N., R. Harada, T. Fujita, and H. Okada. 1989. Monoclonal antibodies capable of causing hemolysis of neuraminidase-treated human erythrocytes by homologous complement. J. Immunol. 143:2262.
9. Sugita, Y., T. Tobe, E. Oda, M. Tomita, K. Yasukawa, N. Yamaji, T. Takemoto, K. Furuichi, M. Takayama, and S. Yano. 1989. Molecular cloning and characterization of MACIF, an inhibitor of membrane channel formation of complement. J. Biochem. 106:555.
10. Seya, T., T. Hara, M. Matsumoto, and H. Akedo. 1990. Quantitative analysis of membrane cofactor protein (MCP) of complement: high expression of MCP on human leukemia cell lines, which is down-regulated during cell differentiation. J. Immunol. 145:238.
11. Blok, V. T., M. R. Daba, O. M. Tijsma, M. G. Weissglas, L. J. van den Broek, and A. Gorter. 2000. A possible role of CD46 for the protection in vivo of human renal tumor cells from complement-mediated damage. Lab. Invest. 80:335.
12. Coral, S., E. Fonsatti, L. Sigalotti, C. De Nardo, A. Visintin, G. Nardi, F. Colizzi, M. P. Colombo, G. Romano, M. Altomonte, and M. Maio. 2000. Overexpression of protectin (CD59) down-modulates the susceptibility of human melanoma cells to homologous complement. J. Cell. Physiol. 185:317.
13. Guc, D., H. Canpinar, C. Kucukaksu, and E. Kansu. 2000. Expression of complement regulatory proteins CR1, DAF, MCP and CD59 in haematological malignancies. Eur. J. Haematol. 64:3.
14. Murray, K. P., S. Mathure, R. Kaul, S. Khan, L. F. Carson, L. B. Twiggs, M. G. Martens, and A. Kaul. 2000. Expression of complement regulatory proteins-CD35, CD46, CD55, and CD59-in benign and malignant endometrial tissue. Gynecol. Oncol. 76:176.
15. Spiller, O. B., O. Criado-Garcia, S. Rodriguez De Cordoba, and B. P. Morgan. 2000. Cytokine-mediated up-regulation of CD55 and CD59 protects human hepatoma cells from complement attack. Clin. Exp. Immunol. 121:234.
16. Jurianz, K., S. Ziegler, N. Donin, Y. Reiter, Z. Fishelson, and M. Kirschfink. 2001. K562 erythroleukemic cells are equipped with multiple mechanisms of resistance to lysis by complement. Int. J. Cancer 93:848.
17. Terachi, T., G. Stanescu, J. E. Pontes, M. E. Medof, and M. J. Caulfield. 1991. Coexistence of autologous antibodies and decay-accelerating factor, an inhibitor of complement, on human renal tumor cells. Cancer Res. 51:2521.
18. Baranyi, L., K. Baranji, H. Takizawa, N. Okada, and H. Okada. 1994. Cell-surface bound complement regulatory activity is necessary for the in vivo survival of KDH-8 rat hepatoma. Immunology 82:522.
19. Chen, S., T. Caragine, N. K. Cheung, and S. Tomlinson. 2000. CD59 expressed on a tumor cell surface modulates decay-accelerating factor expression and enhances tumor growth in a rat model of human neuroblastoma. Cancer Res. 60:3013.
20. Durrant, L. G., and I. Spendlove. 2001. Immunization against tumor cell surface complement-regulatory proteins. Curr. Opin. Investig. Drugs 2:959.
21. Fonsatti, E., M. Altomonte, S. Coral, C. De Nardo, E. Lamaj, L. Sigalotti, P. G. Natali, and M. Maio. 2000. Emerging role of protectin (CD59) in humoral immunotherapy of solid malignancies. Clin. Ter. 151:187.
22. Treon, S. P., C. Mitsiades, N. Mitsiades, G. Young, D. Doss, R. Schlossman, and K. C. Anderson. 2001. Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies. J. Immunother. 24:263.
23. Fujiwara, H., S. C. Clark, and T. Hamaoka. 1996. Cellular and molecular mechanisms underlying IL-12-induced tumor regression. Ann. NY Acad. Sci. 795:294.
24. Zou, J. P., N. Yamamoto, T. Fujii, H. Takenaka, M. Kobayashi, S. H. Herrmann, S. F. Wolf, H. Fujiwara, and T. Hamaoka. 1995. Systemic administration of rIL-12 induces complete tumor regression and protective immunity: response is correlated with a striking reversal of suppressed IFN-γ production by anti-tumor T cells. Int. Immunol. 7:1135.
25. Ogawa, M., T. Tsutsui, J. P. Zou, J. Mu, R. Wijesuriya, W. G. Yu, S. Herrmann, T. Kubo, H. Fujiwara, and T. Hamaoka. 1997. Enhanced induction of very late antigen 4/lymphocyte function-associated antigen 1-dependent T-cell migration to tumor sites following administration of interleukin 12. Cancer Res. 57:2216.
26. Li, B., C. Sallee, M. Dehoff, S. Foley, H. Molina, and V. M. Holers. 1993. Mouse Crry/p65: characterization of monoclonal antibodies and the tissue distribution of a functional homologue of human MCP and DAF. J. Immunol. 151:4295.
27. Molina, H., W. Wong, T. Kinoshita, C. Brenner, S. Foley, and V. M. Holers. 1992. Distinct receptor and regulatory properties of recombinant mouse complement receptor 1 (CR1) and Crry, the two genetic homologues of human CR1. J. Exp. Med. 175:121.
28. Foley, S., B. Li, M. Dehoff, H. Molina, and V. M. Holers. 1993. Mouse Crry/p65 is a regulator of the alternative pathway of complement activation. Eur. J. Immunol. 23:1381.
29. Irie, R. F. 1971. Antigenic cross-reactivity between primary spontaneous mouse mammary tumors and their transplantable ascites tumors. Cancer Res. 31:1682.
30. Stewart, G. A., and D. R. Stanworth. 1975. The effect of acid treatment upon the susceptibility of rabbit IgG to proteolytic cleavage with various enzymes. Immunochemistry 12:713.
31. Ohta, R., M. Imai, Y. Fukuoka, T. Miwa, N. Okada, and H. Okada. 1999. Characterization of mouse DAF on transfectant cells using monoclonal antibodies which recognize different epitopes. Microbiol. Immunol. 43:1045.
32. Harris, C. L., S. M. Hanna, M. Mizuno, D. S. Holt, K. J. Marchbank, and B. P. Morgan. 2003. Characterization of the mouse analogues of CD59 using novel monoclonal antibodies: tissue distribution and functional comparison. Immunology 109:117.
33. Okada, N., and H. Okada. 1978. Activation of complement by spontaneous leukemic cells of AKR mice. Int. J. Cancer 22:282.
34. Varsano, S., L. Rashkovsky, H. Shapiro, D. Ophir, and T. Mark-Bentankur. 1998. Human lung cancer cell lines express cell membrane complement inhibitory proteins and are extremely resistant to complement-mediated lysis; a comparison with normal human respiratory epithelium in vitro, and an insight into mechanism(s) of resistance. Clin. Exp. Immunol. 113:173.
35. Blok, V. T., M. R. Daha, O. Tijsma, C. L. Harris, B. P. Morgan, G. J. Fleuren, and A. Gorter. 1998. A bispecific monoclonal antibody directed against both the membrane-bound complement regulator CD55 and the renal tumor-associated antigen G250 enhances C3 deposition and tumor cell lysis by complement. J. Immunol. 160:3437.
36. Spendlove, L., L. Li, V. Potter, D. Christiansen, B. E. Loveland, and L. G. Durrant. 2000. A therapeutic human anti-idiotypic antibody mimics CD55 in three distinct regions. Eur. J. Immunol. 30:2944.
37. Gelderman, K. A., P. J. Kuppen, W. Bruin, G. J. Fleuren, and A. Gorter. 2002. Enhancement of the complement activating capacity of 17-1A mAb to overcome the effect of membrane-bound complement regulatory proteins on colorectal carcinoma. Eur. J. Immunol. 32:128.
38. Gelderman, K. A., V. T. Blok, G. J. Fleuren, and A. Gorter. 2002. The inhibitory effect of CD46, CD55, and CD59 on complement activation after immunotherapeutic treatment of cervical carcinoma cells with monoclonal antibodies or bispecific monoclonal antibodies. Lab. Invest. 82:483.
39. Mead, R., S. J. Hinchliffe, and B. P. Morgan. 1999. Molecular cloning, expression and characterization of the rat analogue of human membrane cofactor protein (MCP/CD46). Immunology 98:137.
40. Tsujimura, A., K. Shida, M. Kitamura, M. Nomura, J. Takeda, H. Tanaka, M. Matsumoto, K. Matsumiya, A. Okuyama, Y. Nishimune, et al. 1998. Molecular cloning of a murine homologue of membrane cofactor protein (CD46): preferential expression in testicular germ cells. Biochem. J. 330:163.
41. Miwa, T., M. Nonaka, N. Okada, S. Wakana, T. Shiroishi, and H. Okada. 1998. Molecular cloning of rat and mouse membrane cofactor protein (MCP, CD46): preferential expression in testis and close linkage between the mouse Mcp and Cr2 genes on distal chromosome 1. Immunogenetics 48:363.
42. Caragine, T. A., N. Okada, A. B. Frey, and S. Tomlinson. 2002. A tumor-expressed inhibitor of the early but not late complement lytic pathway enhances tumor growth in a rat model of human breast cancer. Cancer Res. 62:1110.
43. Seto, M., T. Takahashi, S. Nakamura, Y. Matsudaira, and Y. Nishizuka. 1983. In vivo antitumor effects of monoclonal antibodies with different immunoglobulin classes. Cancer Res. 43:4768.
44. Ramos, O. F., C. Kai, E. Yefenof, and E. Klein. 1988. The elevated natural killer sensitivity of targets carrying surface-attached C3 fragments requires the availability of the iC3b receptor (CR3) on the effectors. J. Immunol. 140:1239.
45. Bara, S., and T. F. Lint. 1987. The third component of complement (C3) bound to tumor target cells enhances their sensitivity to killing by activated macrophages. J. Immunol. 138:1303.
46. Gorter, A., and S. Meri. 1999. Immune evasion of tumor cells using membrane-bound complement regulatory proteins. Immunol. Today 20:576.
47. Fernandez-Centeno, E., G. de Ojeda, J. M. Rojo, and P. Portoles. 2000. Crry/p65, a membrane complement regulatory protein, has costimulatory properties on mouse T cells. J. Immunol. 164:4533.
48. Sulica, A., P. Morel, D. Metes, and R. B. Herberman. 2001. Ig-binding receptors on human NK cells as effector and regulatory surface molecules. Int. Rev. Immunol. 20:371.